Published in Blood Weekly, May 16th, 2002
"Visilizumab is a humanized anti-CD3 monoclonal antibody characterized by a mutated IgG2 isotype, lack of binding to Fc-receptors and ability to induce apoptosis selectively in activated T cells," according to Dr. Paul A. Carpenter and colleagues at the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle, Rockefeller University in New York City, and Protein Design Labs in Fremont, California.
Visilizumab was safe and effective against...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.